G-code: Procedures and professional services (temporary) Procedures and professional services (temporary)
2,011 codes
Billing context
G-codes are temporary codes for professional services and procedures that would otherwise be coded in CPT.
| Code | Long descriptor | Payment limit (Q4 2026) | Added | Status |
|---|---|---|---|---|
| G0684 | Application of a premarket approval (pma), 510(k), 361 human cells, tissues or cellular and tissue-based products (hct/p) non-sheet form skin substitute graft for a wound surface greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area or part thereof, or each additional 1% of body area of infants and children, or part thereof (list separately in addition to code for primary procedure) | — | Jan 1, 2026 | Active |
| G0685 | Algorithm-based assessment of likelihood of autism spectrum disorder (asd), derived from validated analysis of eye-gaze data or other technology | — | Oct 1, 2026 | Active |
| G0908 | Most recent hemoglobin (hgb) level > 12.0 g/dl | — | Jan 1, 2012 | Ended Dec 31, 2014 |
| G0909 | Hemoglobin level measurement not documented, reason not given | — | Jan 1, 2012 | Ended Dec 31, 2014 |
| G0910 | Most recent hemoglobin level <= 12.0 g/dl | — | Jan 1, 2012 | Ended Dec 31, 2014 |
| G0913 | Improvement in visual function achieved within 90 days following cataract surgery | — | Jan 1, 2012 | Active |
| G0914 | Patient care survey was not completed by patient | — | Jan 1, 2012 | Active |
| G0915 | Improvement in visual function not achieved within 90 days following cataract surgery | — | Jan 1, 2012 | Active |
| G0916 | Satisfaction with care achieved within 90 days following cataract surgery | — | Jan 1, 2012 | Active |
| G0917 | Patient care survey was not completed by patient | — | Jan 1, 2012 | Active |
| G0918 | Satisfaction with care not achieved within 90 days following cataract surgery | — | Jan 1, 2012 | Active |
| G0919 | Influenza immunization ordered or recommended (to be given at alternate location or alternate provider); vaccine not available at time of visit | — | Jan 1, 2012 | Ended Dec 31, 2014 |
| G0920 | Type, anatomic location, and activity all documented | — | Jan 1, 2012 | Ended Dec 31, 2014 |
| G0921 | Documentation of patient reason(s) for not being able to assess (e.g., patient refuses endoscopic and/or radiologic assessment) | — | Jan 1, 2012 | Ended Dec 31, 2014 |
| G0922 | No documentation of disease type, anatomic location, and activity, reason not given | — | Jan 1, 2012 | Ended Dec 31, 2014 |
| G1000 | Clinical decision support mechanism applied pathways, as defined by the medicare appropriate use criteria program | — | Jan 1, 2020 | Ended Mar 31, 2020 |
| G1001 | Clinical decision support mechanism evicore, as defined by the medicare appropriate use criteria program | — | Jan 1, 2020 | Ended Dec 31, 2024 |
| G1002 | Clinical decision support mechanism medcurrent, as defined by the medicare appropriate use criteria program | — | Jan 1, 2020 | Ended Dec 31, 2024 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | — | Jan 1, 2020 | Ended Dec 31, 2024 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | — | Jan 1, 2020 | Ended Dec 31, 2024 |
| G1005 | Clinical decision support mechanism national imaging associates, as defined by the medicare appropriate use criteria program | — | Jan 1, 2020 | Ended Dec 31, 2020 |
| G1006 | Clinical decision support mechanism test appropriate, as defined by the medicare appropriate use criteria program | — | Jan 1, 2020 | Ended Dec 31, 2020 |
| G1007 | Clinical decision support mechanism aim specialty health, as defined by the medicare appropriate use criteria program | — | Jan 1, 2020 | Ended Dec 31, 2024 |
| G1008 | Clinical decision support mechanism cranberry peak, as defined by the medicare appropriate use criteria program | — | Jan 1, 2020 | Ended Dec 31, 2024 |
| G1009 | Clinical decision support mechanism sage health management solutions, as defined by the medicare appropriate use criteria program | — | Jan 1, 2020 | Ended Mar 31, 2022 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | — | Jan 1, 2020 | Ended Dec 31, 2024 |
| G1011 | Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria programNOC / NOS | — | Jan 1, 2020 | Ended Dec 31, 2024 |
| G1012 | Clinical decision support mechanism agilemd, as defined by the medicare appropriate use criteria program | — | Apr 1, 2020 | Ended Dec 31, 2024 |
| G1013 | Clinical decision support mechanism evidencecare imagingcare, as defined by the medicare appropriate use criteria program | — | Apr 1, 2020 | Ended Dec 31, 2024 |
| G1014 | Clinical decision support mechanism inveniqa semantic answers in medicine, as defined by the medicare appropriate use criteria program | — | Apr 1, 2020 | Ended Dec 31, 2024 |
| G1015 | Clinical decision support mechanism reliant medical group, as defined by the medicare appropriate use criteria program | — | Apr 1, 2020 | Ended Dec 31, 2024 |
| G1016 | Clinical decision support mechanism speed of care, as defined by the medicare appropriate use criteria program | — | Apr 1, 2020 | Ended Dec 31, 2024 |
| G1017 | Clinical decision support mechanism healthhelp, as defined by the medicare appropriate use criteria program | — | Apr 1, 2020 | Ended Dec 31, 2024 |
| G1018 | Clinical decision support mechanism infinx, as defined by the medicare appropriate use criteria program | — | Apr 1, 2020 | Ended Dec 31, 2024 |
| G1019 | Clinical decision support mechanism logicnets, as defined by the medicare appropriate use criteria program | — | Apr 1, 2020 | Ended Dec 31, 2024 |
| G1020 | Clinical decision support mechanism curbside clinical augmented workflow, as defined by the medicare appropriate use criteria program | — | Oct 1, 2020 | Ended Dec 31, 2024 |
| G1021 | Clinical decision support mechanism ehealthline clinical decision support mechanism, as defined by the medicare appropriate use criteria program | — | Oct 1, 2020 | Ended Dec 31, 2024 |
| G1022 | Clinical decision support mechanism intermountain clinical decision support mechanism, as defined by the medicare appropriate use criteria program | — | Oct 1, 2020 | Ended Dec 31, 2024 |
| G1023 | Clinical decision support mechanism persivia clinical decision support, as defined by the medicare appropriate use criteria program | — | Oct 1, 2020 | Ended Dec 31, 2024 |
| G1024 | Clinical decision support mechanism radrite, as defined by the medicare appropriate use criteria program | — | Jan 1, 2022 | Ended Dec 31, 2024 |
| G1025 | Patient-months where there are more than one medicare capitated payment (mcp) provider listed for the month | — | Jan 1, 2022 | Active |
| G1026 | The number of adult patient-months in the denominator who were on maintenance hemodialysis using a catheter continuously for three months or longer under the care of the same practitioner or group partner as of the last hemodialysis session of the reporting month | — | Jan 1, 2022 | Active |
| G1027 | The number of adult patient-months in the denominator who were on maintenance hemodialysis under the care of the same practitioner or group partner as of the last hemodialysis session of the reporting month using a catheter continuously for less than three months | — | Jan 1, 2022 | Active |
| G1028 | Take-home supply of nasal naloxone; 2-pack of 8mg per 0.1 ml nasal spray (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | — | Jan 1, 2022 | Active |
| G2000 | Blinded administration of convulsive therapy procedure, either electroconvulsive therapy (ect, current covered gold standard) or magnetic seizure therapy (mst, non-covered experimental therapy), performed in an approved ide-based clinical trial, per treatment session | — | Aug 1, 2018 | Active |
| G2001 | Brief (20 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.) | — | Jan 1, 2019 | Active |
| G2002 | Limited (30 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.) | — | Jan 1, 2019 | Active |
| G2003 | Moderate (45 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.) | — | Jan 1, 2019 | Active |
| G2004 | Comprehensive (60 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.) | — | Jan 1, 2019 | Active |
| G2005 | Extensive (75 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.) | — | Jan 1, 2019 | Active |
| G2006 | Brief (20 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.) | — | Jan 1, 2019 | Active |
| G2007 | Limited (30 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.) | — | Jan 1, 2019 | Active |
| G2008 | Moderate (45 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.) | — | Jan 1, 2019 | Active |
| G2009 | Comprehensive (60 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.) | — | Jan 1, 2019 | Active |
| G2010 | Remote evaluation of recorded video and/or images submitted by an established patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment | — | Jan 1, 2019 | Active |
| G2011 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention, 5-14 minutes | — | Jan 1, 2019 | Active |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | — | Jan 1, 2019 | Ended Dec 31, 2024 |
| G2013 | Extensive (75 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.) | — | Jan 1, 2019 | Active |
| G2014 | Limited (30 minutes) care plan oversight. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.) | — | Jan 1, 2019 | Active |
| G2015 | Comprehensive (60 mins) home care plan oversight. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility.) | — | Jan 1, 2019 | Active |
| G2020 | Services for high intensity clinical services associated with the initial engagement and outreach of beneficiaries assigned to the sip component of the pcf model (do not bill with chronic care management codes) | — | Apr 1, 2021 | Active |
| G2021 | Health care practitioners rendering treatment in place (tip) | — | Jan 1, 2020 | Active |
| G2022 | A model participant (ambulance supplier/provider), the beneficiary refuses services covered under the model (transport to an alternate destination/treatment in place) | — | Jan 1, 2020 | Active |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | — | Mar 1, 2020 | Ended May 11, 2023 |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | — | Mar 1, 2020 | Ended May 11, 2023 |
| G2025 | Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only | — | Jan 27, 2020 | Active |
| G2058 | Chronic care management services, each additional 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month (list separately in addition to code for primary procedure). (do not report g2058 for care management services of less than 20 minutes additional to the first 20 minutes of chronic care management services during a calendar month). (use g2058 in conjunction with 99490). (do not report 99490, g2058 in the same calendar month as 99487, 99489, 99491)). | — | Jan 1, 2020 | Ended Dec 31, 2020 |
| G2061 | Qualified nonphysician healthcare professional online assessment and management service, for an established patient, for up to seven days, cumulative time during the 7 days; 5-10 minutes | — | Jan 1, 2020 | Ended Dec 31, 2020 |
| G2062 | Qualified nonphysician healthcare professional online assessment and management service, for an established patient, for up to seven days, cumulative time during the 7 days; 11-20 minutes | — | Jan 1, 2020 | Ended Dec 31, 2020 |
| G2063 | Qualified nonphysician healthcare professional online assessment and management service, for an established patient, for up to seven days, cumulative time during the 7 days; 21 or more minutes | — | Jan 1, 2020 | Ended Dec 31, 2020 |
| G2064 | Comprehensive care management services for a single high-risk disease, e.g., principal care management, at least 30 minutes of physician or other qualified health care professional time per calendar month with the following elements: one complex chronic condition lasting at least 3 months, which is the focus of the care plan, the condition is of sufficient severity to place patient at risk of hospitalization or have been the cause of a recent hospitalization, the condition requires development or revision of disease-specific care plan, the condition requires frequent adjustments in the medication regimen, and/or the management of the condition is unusually complex due to comorbidities | — | Jan 1, 2020 | Ended Dec 31, 2021 |
| G2065 | Comprehensive care management for a single high-risk disease services, e.g. principal care management, at least 30 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month with the following elements: one complex chronic condition lasting at least 3 months, which is the focus of the care plan, the condition is of sufficient severity to place patient at risk of hospitalization or have been cause of a recent hospitalization, the condition requires development or revision of disease-specific care plan, the condition requires frequent adjustments in the medication regimen, and/or the management of the condition is unusually complex due to comorbidities | — | Jan 1, 2020 | Ended Dec 31, 2021 |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | — | Jan 1, 2020 | Ended Dec 31, 2023 |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) | — | Jan 1, 2020 | Active |
| G2068 | Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) | — | Jan 1, 2020 | Active |
| G2069 | Medication assisted treatment, buprenorphine (injectable) administered on a monthly basis; bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) | — | Jan 1, 2020 | Active |
| G2070 | Medication assisted treatment, buprenorphine (implant insertion); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) | — | Jan 1, 2020 | Ended Dec 31, 2024 |
| G2071 | Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) | — | Jan 1, 2020 | Ended Dec 31, 2024 |
| G2072 | Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) | — | Jan 1, 2020 | Ended Dec 31, 2024 |
| G2073 | Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) | — | Jan 1, 2020 | Active |
| G2074 | Medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) | — | Jan 1, 2020 | Active |
| G2075 | Medication assisted treatment, medication not otherwise specified; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program)NOC / NOS | — | Jan 1, 2020 | Active |
| G2076 | Intake activities, including initial medical examination that is conducted by an appropriately licensed practitioner and preparation of a care plan, which may be informed by administration of a standardized, evidence-based assessment, and that includes the patient's goals and mutually agreed-upon actions for the patient to meet those goals, including harm reduction interventions; the patient's needs and goals in the areas of education, vocational training, and employment; and the medical and psychiatric, psychosocial, economic, legal, housing, physical activity and/or nutrition needs and other recovery support services that a patient needs and wishes to pursue, conducted by an appropriately licensed/credentialed personnel (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to each primary code | — | Jan 1, 2020 | Active |
| G2077 | Periodic assessment; assessing periodically by an otp practitioner and includes a review of moud dosing, treatment response, other substance use disorder treatment needs, responses and patient-identified goals, and other relevant physical, nutrition and psychiatric treatment needs and goals; may be informed by administration of a standardized, evidence-based assessment, or the need and interest for harm reduction interventions and recovery support services (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to each primary code | — | Jan 1, 2020 | Active |
| G2078 | Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | — | Jan 1, 2020 | Active |
| G2079 | Take-home supply of buprenorphine (oral); up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | — | Jan 1, 2020 | Active |
| G2080 | Each additional 30 minutes of counseling in a week of medication assisted treatment, (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | — | Jan 1, 2020 | Active |
| G2081 | Patients age 66 and older in institutional special needs plans (snp) or residing in long-term care with a pos code 32, 33, 34, 54 or 56 for more than 90 consecutive days during the measurement period | — | Jan 1, 2020 | Active |
| G2082 | Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation | — | Jan 1, 2020 | Active |
| G2083 | Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation | — | Jan 1, 2020 | Active |
| G2086 | Office-based treatment for opioid use disorder, including development of the treatment plan, care coordination, individual therapy and group therapy and counseling; at least 70 minutes in the first calendar month | — | Jan 1, 2020 | Active |
| G2087 | Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month | — | Jan 1, 2020 | Active |
| G2088 | Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; each additional 30 minutes beyond the first 120 minutes (list separately in addition to code for primary procedure) | — | Jan 1, 2020 | Active |
| G2089 | Most recent hemoglobin a1c (hba1c) level 7.0 to 9.0% | — | Jan 1, 2020 | Ended Dec 31, 2020 |
| G2090 | Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period | — | Jan 1, 2020 | Active |
| G2091 | Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and an advanced illness diagnosis during the measurement period or the year prior to the measurement period | — | Jan 1, 2020 | Active |
| G2092 | Angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) or angiotensin receptor-neprilysin inhibitor (arni) therapy prescribed or currently being taken | — | Jan 1, 2020 | Active |
| G2093 | Documentation of medical reason(s) for not prescribing ace inhibitor or arb or arni therapy (e.g., hypotensive patients who are at immediate risk of cardiogenic shock, hospitalized patients who have experienced marked azotemia, allergy, intolerance, other medical reasons) | — | Jan 1, 2020 | Active |
| G2094 | Documentation of patient reason(s) for not prescribing ace inhibitor or arb or arni therapy (e.g., patient declined, other patient reasons) | — | Jan 1, 2020 | Active |
| G2095 | Documentation of system reason(s) for not prescribing ace inhibitor or arb or arni therapy (e.g., other system reasons) | — | Jan 1, 2020 | Ended Dec 31, 2022 |